Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service tumor ablation cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 15% on average (83 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 1 | 367 | 40% |
| 2020 | 2 | 336 | 43% |
| 2021 | 3 | 313 | 48% |
| 2022 | 4 | 366 | 52% |
| 2023 | 4 | 335 | 56% |
| 2024 | 3 | 334 | 59% |
| 2025 from claims | – | 298 241–349 | 61% |
| 2026 forecast | – | 303 237–380 | 62% |
| 2027 forecast | – | 307 228–406 | 62% |
| 2028 forecast | – | 311 220–429 | 63% |
| 2029 forecast | – | 315 214–452 | 64% |
| 2030 forecast | – | 319 209–473 | 65% |
Percutaneous liver, kidney, lung, and bone tumor ablation. Professional codes (what the surgeon bills): CPT 47382, 47383, 50592, 50593, 32998, 20982, 20983.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in North Carolina; 3 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% hospital outpatient.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 3 | 795+1.4%/yr | +1.4%/yr | 0.4 | 0% | 1,250 in 2030+7.8%/yr |
| Texas | 6 | 772−0.3%/yr | −0.3%/yr | 0.4 | 0% | 1,010 in 2030+4.6%/yr |
| Georgia | 2 | 335+1.7%/yr | +1.7%/yr | 0.4 | 0% | 260 in 2030−3.9%/yr |
| Virginia | 1 | 278+2.6%/yr | +2.6%/yr | 0.3 | 0% | 470 in 2030+9%/yr |
| Maryland | 5 | 276+7%/yr | +7%/yr | 0.3 | 0% | 670 in 2030+16%/yr |
| South Carolina | 2 | 220−0.1%/yr | −0.1%/yr | 0.3 | 0% | 260 in 2030+3.1%/yr |
| Tennessee | 3 | 213+0.5%/yr | +0.5%/yr | 0.3 | 0% | 280 in 2030+4.6%/yr |
| Louisiana | 0 | 112+4%/yr | +4%/yr | 0.3 | 0% | 290 in 2030+17%/yr |
| Alabama | 0 | 110+2.3%/yr | +2.3%/yr | 0.3 | 0% | 140 in 2030+4.6%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Breast biopsy & localization | 133 | 8,308−3%/yr | −3%/yr | 9.01.3× | 45% | 8,490 in 2030+0.4%/yr |
| Tumor & fibroid embolization | 11 | 795+10%/yr | +10%/yr | 0.81.5× | 63% | 1,900 in 2030+16%/yr |
Tumor ablation in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Florida
Exact Sciences leads with 40% of company spending on these surgeons in 2025, +7 pts on 2024.
In 2025, 18 companies reported engagement with North Carolina’s surgeons worth $234K in consulting, speaking, meals and travel tied to these products, about $78K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 11 clearances and approvals in the category, 5 recalled product lines (3 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 47382 (percut ablate liver rf), commercial plans pay North Carolina’s hospitals a median of $5,963, from $5,320 at the lowest to $5,963 at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.